HLS Therapeutics Inc. (OTCMKTS:HLTRF) Short Interest Down 9.1% in March

HLS Therapeutics Inc. (OTCMKTS:HLTRF) was the recipient of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 2,000 shares, a decrease of 9.1% from the March 15th total of 2,200 shares. Based on an average daily volume of 100 shares, the short-interest ratio is presently 20.0 days.

Analysts Set New Price Targets

Separately, Raymond James lowered their price target on shares of HLS Therapeutics from $6.50 to $5.00 and set a “market perform” rating for the company in a research report on Monday, March 18th.

HLS Therapeutics Stock Performance

OTCMKTS:HLTRF remained flat at $3.85 during midday trading on Tuesday. HLS Therapeutics has a 52 week low of $2.60 and a 52 week high of $4.95. The firm has a 50 day moving average price of $3.24 and a 200-day moving average price of $3.35.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.